{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:01:22Z","timestamp":1779922882558,"version":"3.53.1"},"reference-count":57,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23\/81) of all GT1-infected patients with 9.9% (8\/81) having the Y93C\/H mutation. NS5B RASs showed a prevalence of 14.8% (12\/81) and were only detected in GT1b. Overall 38.3% (31\/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C\/H (p = 0.04).<\/jats:p>","DOI":"10.3390\/v10050223","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T04:17:52Z","timestamp":1524716272000},"page":"223","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-953X","authenticated-orcid":false,"given":"Ruben","family":"Brand\u00e3o","sequence":"first","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-9725","authenticated-orcid":false,"given":"Rute","family":"Marcelino","sequence":"additional","affiliation":[{"name":"Global Health and Tropical Medicine (GHTM), Unit of Medical Microbiology, Instituto de Higiene e Medicina Tropical (IHMT), Universidade NOVA de Lisboa (UNL), 1349-008 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Diogo","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Cabanas","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Costa","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Brogueira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Doen\u00e7as Infeciosas, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ventura","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Doen\u00e7as Infeciosas, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Miranda","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Doen\u00e7as Infeciosas, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Mansinho","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Doen\u00e7as Infeciosas, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-8255","authenticated-orcid":false,"given":"Perp\u00e9tua","family":"Gomes","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, LMCBM, SPC, HEM\u2014Centro Hospitalar Lisboa Ocidental, 1349-019 Lisboa, Portugal"},{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz, CiiEM, ISCSEM, 2829-511 Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Abajobir","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Abajobir","year":"2017","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Institute for Health Metrics and Evaluation (IHME) (2017, October 19). GBD Results Tool. Available online: http:\/\/ghdx.healthdata.org\/gbd-results-tool."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of Hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic Hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with Hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic Hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14656566.2013.795543","article-title":"Hepatitis C therapy with HCV NS5B polymerase inhibitors","volume":"14","author":"Soriano","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.3748\/wjg.v19.i47.8940","article-title":"Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review","volume":"19","author":"Wu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","article-title":"Hepatitis C virus NS5A inhibitors and drug resistance mutations","volume":"20","author":"Nakamoto","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL) (2016). EASL recommendations on treatment of Hepatitis C 2016. J. Hepatol., 61, 373\u2013395.","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bronowicki","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","unstructured":"Bourliere, M., and Bronowicki, J. (2014, January 7\u201311). Ledipasvir\/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Proceedings of the 65th AASLD Meeting, Boston, MA, USA."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S631","DOI":"10.1016\/S0168-8278(16)01554-3","article-title":"Real World Effectiveness of Ledipasvir\/Sofosbuvir in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic HCV\u202f: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts","volume":"64","author":"Curry","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_22","first-page":"1128","article-title":"Baseline and Post-baseline Resistance Analyses of Phase 2\/3 Studies of Ledipasvir\/Sofosbuvir \u00b1 RBV","volume":"60","author":"Park","year":"2014","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Susser, S., Dietz, J., Vermehren, J., Peiffer, K.H., Passmann, S., Perner, D., Berkowski, C., Ferenci, P., Buti, M., and M\u00fcllhaupt, B. (2016, January 13\u201317). European RAVs Database: Frequency and Characteristics of RAVs in treatment-naive and DAA-experienced patients. Proceedings of the International Liver Congress (EASL), Barcelona, Spain.","DOI":"10.1016\/S0168-8278(16)01644-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_26","unstructured":"Dvory-Sobol, H., Doehle, B., Svarovskaia, E., McCarville, J.F., Pang, P., Afdhal, N., Kowdley, K.V., McHutchison, J., Miller, M., and Mo, H. (2014, January 3\u20137). The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir\/Sofosbuvir \u00b1 RBV in the Phase 3 ION Studies. Proceedings of the International Workshop on Antiviral Drug Resistance, Berlin, Germany."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sarrazin, C., Dvory-Sobol, H., and Svarovskaia, E.S. (2015, January 22\u201326). The Prevalence and the Effect of HCV NS5A Resistance-Associated Variants in Patients with Compensated Cirrhosis Treated with Ledipasvir\/Sofosbuvir \u00b1 RBV. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria.","DOI":"10.1016\/S0168-8278(15)30976-4"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dietz, J., Susser, S., Berkowski, C., Perner, D., Zeuzem, S., and Sarrazin, C. (2015). Consideration of viral resistance for optimization of direct antiviral therapy of Hepatitis C virus genotype 1-infected patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134395"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 Hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 Hepatitis, C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Svarovskaia, E.S., Zeuzem, S., and Hedskog, C. (2015, January 22\u201326). Prevalence of Pretreatment NS5A and NS5B Resistance-Associated Variants and Genetic Variation within HCV Subtypes Across Different Countries\/Gilead-Study. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria.","DOI":"10.1016\/S0168-8278(15)31097-7"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12072-015-9624-2","article-title":"HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b","volume":"9","author":"Hirotsu","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.02386-13","article-title":"Hepatitis C virus genetic variability and the presence of NS5B resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors","volume":"58","author":"Cento","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3851\/IMP2091","article-title":"Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor","volume":"17","author":"Plaza","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on Hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of Hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP1760","article-title":"Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients","volume":"16","author":"Parra","year":"2011","journal-title":"Antivir. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3851\/IMP1900","article-title":"NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1\u20135","volume":"16","author":"Vallet","year":"2011","journal-title":"Antivir. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring Hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clinthera.2014.12.012","article-title":"Simeprevir and sofosbuvir for treatment of chronic Hepatitis C infection","volume":"37","author":"Hand","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of Hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_46","first-page":"1134A","article-title":"Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials","volume":"60","author":"Krishnan","year":"2014","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside Hepatitis C virus polymerase inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"Alves","year":"2013","journal-title":"J. Viral Hepat."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Charlton, M., Manns, M., Dvory-Sobol, H., Svarovskaia, E., Doehle, B., Arterburn, S., Yun, C., Brainard, D.M., Mchutchison, J.G., and Miller, M.D. (2016, January 13\u201317). Resistance Analyses for Ledipasvir\/Sofosbuvir-Containing Regimens in patients infected with chronic HCV who have advanced liver disease or are post liver Transplant (SOLAR-1 and -2 Studies). Proceedings of the International Liver Congress (EASL), Barcelona, Spain.","DOI":"10.1016\/S0168-8278(16)01701-3"},{"key":"ref_50","first-page":"1083A","article-title":"Distribution of pre-existing NS5A\/NS5B resistance associated variants in genotype 1B patients with Hepatitis C virus and response to direct acting antivirals","volume":"62","author":"Watabe","year":"2015","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions","volume":"213","author":"Svarovskaia","year":"2016","journal-title":"Infect. Dis. Soc. Am."},{"key":"ref_52","unstructured":"Zeuzem, S., Mizokami, M., Pianko, S., Mangia, A., Han, K.H., Martin, R., Svarovskaia, E., Dvory-Sobol, H., Doehle, B., and Pang, P.S. (2015, January 13\u201317). Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV\/SOF. Proceedings of the AASLD Meeting, San Francisco, CA, USA."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection ASTRAL-1","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S1093","DOI":"10.1016\/S0016-5085(16)33693-9","article-title":"Safety of ABT-493 and ABT-530 co-administered in patients with HCV genotype 1\u20136 infection: Results from the SURVEYOR-I and SURVEYOR-II studies","volume":"150","author":"Kwo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Muir, A.J., Strasser, S., Wang, S., Shafran, S., Bonacini, M., Kwo, P., Wyles, D., Gane, E., Lovell, S.S., and Lin, C.W. (2016, January 13\u201317). High SVR rates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with genotype 3 infection. Proceedings of the International Liver Congress (EASL), Barcelona, Spain.","DOI":"10.1016\/S0168-8278(16)01700-1"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/apt.13882","article-title":"The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-na\u00efve and treatment-experienced) subjects treated with all-oral elbasvir\/grazoprevir regimens in the United States","volume":"45","author":"Elbasha","year":"2017","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/5\/223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:02:13Z","timestamp":1760194933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/5\/223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"alternative-id":["v10050223"],"URL":"https:\/\/doi.org\/10.3390\/v10050223","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]}}}